Chemo plus immunotherapy for mutated advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and understand the study details and sign a consent form.
- You are 18 years or older and have stage IV non-small cell lung cancer (NSCLC).
- Your tumor has a confirmed EGFR, ALK, or ROS1 mutation, and it has progressed after first treatment.
- You are well enough to do daily activities (ECOG 0–1) and you’re expected to live at least 12 weeks.
- Blood tests and organ health (bone marrow, liver, kidneys, etc.) are good enough for treatment.
- There is at least one measurable tumor spot doctors can track on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy can help people with advanced non-small cell lung cancer that carries an EGFR exon 21 mutation and shows PD-L1 expression. The goal is to see if this combination helps shrink tumors or slow cancer growth more effectively.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.